Login to Your Account

Clinic Roundup

Thursday, October 3, 2013
• Durata Therapeutics Inc., of Chicago, presented a comprehensive review of the efficacy, safety and microbiology data of lead candidate, dalbavancin, in acute bacterial skin and skin structure infections.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription